Inmune Bio Appoints Two Independent Directors, Expands Board to Seven

What Happened
Inmune Bio, Inc. filed an 8-K dated September 14, 2026 reporting that on September 8, 2026 the Board approved increasing its size to seven directors and appointed R. Duane Clark II and James Sapirstein as directors. Both appointees are designated independent under Nasdaq Listing Rule 5605 and were also appointed to the Board’s Nominating and Corporate Governance Committee. They will serve until the next annual election and until their successors are elected and qualified.

Key Details

• Board change: size set at seven directors; appointments effective September 8, 2026.
• Compensation: each appointee shall receive, subject to Compensation Committee approval, an option to purchase 100,000 shares under the company’s 2021 Stock Incentive Plan (vesting in 36 equal monthly installments starting one month after grant).
• Cash retainer and expenses: each will receive an annual cash retainer of $50,000 (paid quarterly, prorated as needed) and reimbursement for reasonable board-related expenses.
• Other items: both will enter the company’s standard indemnification agreement; Board found no family relationships or reportable transactions requiring disclosure under Item 404(a) of Regulation S‑K.

Why It Matters
The appointments add two seasoned biopharma executives with more than four decades of industry experience each—Clark with deep rare-disease and commercialization leadership at Sanofi, and Sapirstein with extensive business-development, commercialization and public-company experience. For investors, this strengthens the company’s board oversight and commercial/strategic expertise while maintaining independent director composition per Nasdaq rules. The planned option grants and retainers are standard director compensation; they imply modest potential equity dilution over time if exercised.